Cancer Therapeutics (CT) Program
The overarching goals of the Cancer Therapeutics (CT) program are to advance the translation of ideas through: 1) the development and translation of new therapeutic agents; 2) biotechnology approaches (i.e., new therapies or drug-delivery vehicles, innovative imaging technologies, and data analysis systems) to enhance new cancer treatments and diagnostics; and 3) to develop and initiate innovative clinical trials with focus on priority cancers.
The thematic areas and specific aims of the CT Program are:
- Drug Development and Delivery: To foster the development and translation of new therapeutic agents.
- Biotechnology: To utilize biotechnology to develop new cancer treatments and diagnostics.
- Developmental Therapeutics: To develop and initiate innovative clinical trials with a focus on priority cancers.
- Lacey McNally, PhD Program Co-Leader
-
Kathleen Moore, MD
Program Co-Leader
Explore Supportive Care services for your cancer journey
Learn More
Find out if you’re at risk for diabetes
Learn More
See what our commitment to ending diabetes in this century means for you
Learn More
-
OU Health Sciences Center Researcher Studies Possible Treatment for Diseases with Social Deficits
People with autism spectrum disorder and other neuropsychiatric diseases that heavily feature social deficits have no drugs available to treat their ...
Read More -
Beating Cervical Cancer in Oklahoma
Each year in the US, approximately 4,000 women die of cervical cancer, and 13,000 new cases are diagnosed. The CDC reports that of all of the cervical ...
Read More -
OU Health Stephenson Cancer Center to Double Phase 1 Clinical Trials With Federal Build Back ...
OU Health Stephenson Cancer Center at the University of Oklahoma Health Sciences Center, which offers the only Phase 1 clinical trials program in ...
Read More